RT Journal Article
SR Electronic
A1 Cunningham, Muriel
T1 Edoxaban Noninferior to Warfarin in the ENGAGE AF-TIMI 48 Trial
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 20
SP 24
OP 25
DO 10.1177/155989771320012
UL http://mdc.sagepub.com/content/13/20/24.abstract
AB Warfarin is widely used for stroke prevention in patients with atrial fibrillation (AF) but novel oral anticoagulants have been developed that may be just as effective [Dogliotti A et al. Clin Cardiol 2013]. Edoxaban is a direct oral factor Xa inhibitor administered once daily with a rapid onset of action. Warfarin and two doses of edoxaban were compared in the Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation — Thrombolysis in Myocardial Infarction 48 study [ENGAGE AF-TIMI 48; Giugliano RP et al. N Engl J Med 2013].